Trujillo-Estrada Laura, Dávila José Carlos, Sánchez-Mejias Elisabeth, Sánchez-Varo Raquel, Gomez-Arboledas Angela, Vizuete Marisa, Vitorica Javier, Gutiérrez Antonia
Department Biología Celular, Genética y Fisiología, Facultad de Ciencias, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Spain Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.
Department Bioquímica y Biología Molecular, Facultad de Farmacia. Universidad de Sevilla, Spain Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain Instituto de Biomedicina de Sevilla (IBIS)-Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain.
J Alzheimers Dis. 2014;42(2):521-41. doi: 10.3233/JAD-140495.
The progressive cognitive decline leading to dementia in Alzheimer's disease (AD) patients is the consequence of a severe loss of synapses and neurons affecting particular cell subpopulations in selected brain areas, with the subiculum being one of the earliest regions displaying severe atrophy and pathology. The lack of significant neuronal loss in most AD models is, in fact, the major shortcoming for the preclinical evaluation of drugs that could have greater potential in patients to alleviate or prevent this disease. In this study, using immunohistochemical and stereological approaches, we have analyzed the histopathological events in the subiculum of AβPP751SwedLondon/PS1M146L mice, a transgenic model that displays neuronal vulnerability at early ages in hippocampus and entorhinal cortex. Our results indicate that the subiculum is the earliest affected region in the hippocampus, showing a selective early loss of both principal neurons (28%) and SOM-positive interneurons (69%). In addition, our data demonstrate the existence of an early axonal and synaptic pathology, which may represent the beginning of the synaptic disruption and loss. These neurodegenerative processes occur in parallel, and closely related, with the onset and accelerated progression of the extracellular amyloid-β deposition, thus suggesting plaques as major contributors of neuronal/axonal damage. Data reported here indicate that this AD model displays a selective AD-like neurodegenerative phenotype in highly vulnerable regions, including the subiculum, and therefore can be a very useful model for testing the therapeutic ability of potential compounds to protect neurons and ameliorate disease symptoms.
阿尔茨海默病(AD)患者中导致痴呆的进行性认知衰退是特定脑区中特定细胞亚群的突触和神经元严重丧失的结果,海马下托是最早出现严重萎缩和病理变化的区域之一。事实上,大多数AD模型中缺乏明显的神经元丧失,是对那些可能在患者中具有更大潜力来缓解或预防这种疾病的药物进行临床前评估的主要缺点。在本研究中,我们使用免疫组织化学和体视学方法,分析了AβPP751SwedLondon/PS1M146L小鼠海马下托中的组织病理学事件,该转基因模型在幼年时海马体和内嗅皮质中显示出神经元易损性。我们的结果表明,海马下托是海马体中最早受影响的区域,显示出主要神经元(28%)和SOM阳性中间神经元(69%)均有选择性早期丧失。此外,我们的数据证明存在早期轴突和突触病理学变化,这可能代表突触破坏和丧失的开始。这些神经退行性过程与细胞外淀粉样β沉积的发生和加速进展同时出现且密切相关,因此提示斑块是神经元/轴突损伤的主要促成因素。此处报告的数据表明,该AD模型在包括海马下托在内的高度易损区域表现出选择性的AD样神经退行性表型,因此可以成为测试潜在化合物保护神经元和改善疾病症状治疗能力的非常有用的模型。